Floatz logo

js212

Advanced Malignant Solid Tumours

Shanghai Junshi Bioscience Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Advanced Malignant Solid Tumours cohort.

Asset / SponsorPhaseRating
Sctb41
Sinocelltech Ltd.
Phase 1/2CC
js212 for
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2CC
Sctb14
Sinocelltech Ltd.
Phase 1/2CC

Same molecule, other indications

js212 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) MutationsDormant
CCC
Indicative ·
53 / 100
View asset →
Advanced Malignant Solid TumorsDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →